1. Home
  2. EVC vs CTMX Comparison

EVC vs CTMX Comparison

Compare EVC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

SELL

Current Price

$6.51

Market Cap

683.9M

Sector

Industrials

ML Signal

SELL

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

SELL

Current Price

$2.42

Market Cap

716.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EVC
CTMX
Founded
1996
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.9M
716.9M
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
EVC
CTMX
Price
$6.51
$2.42
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $12.25
AVG Volume (30 Days)
1.2M
★ 4.0M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 2.97%
N/A
EPS Growth
★ 47.59
N/A
EPS
★ 0.32
N/A
Revenue
★ $536,034,000.00
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.24
P/E Ratio
★ $21.16
$22.58
Revenue Growth
★ N/A
N/A
52 Week Low
$1.95
$2.43
52 Week High
$13.74
$8.21

Technical Indicators

Market Signals
Indicator
EVC
CTMX
Relative Strength Index (RSI) 22.52 31.47
Support Level $2.89 N/A
Resistance Level $10.09 $3.93
Average True Range (ATR) 0.30 0.14
MACD -0.04 -0.01
Stochastic Oscillator 3.14 2.00

Price Performance

Historical Comparison
EVC
CTMX

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: